Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Siguret

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Pathologie-Biologie|July 6, 2007
[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy]V Siguret
Annales De Biologie Clinique|March 1, 1997
[Biological diagnosis of hemoglobinopathies by phenotype analysis]V Siguret, J P Andreux
Annales De Biologie Clinique|October 1, 1998
[Evaluation of hemostasis in venous thromboembolism pathology]P Gaussem, V Siguret, M Aiach
La Revue De Medecine Interne|April 6, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]C Moreau, V Siguret, M-A Loriot
Journal of Thrombosis and Haemostasis : JTH|August 9, 2011
No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudyV Siguret, I Gouin-Thibault, E Pautas, et al.
La Revue De Medecine Interne|March 26, 2003
[Oral anticoagulants in the elderly]M Debray, E Pautas, P Couturier, et al.
Pathologie-Biologie|May 1, 1989
[Frequency and severity of systemic infections caused by Streptococcus mitis and sanguis II in neutropenic children]T Leblanc, G Leverger, G Arlet, et al.
Journal of the American Geriatrics Society|December 16, 1998
Venous thrombosis in older people: prevalence of the factor V gene mutation Q506E André, V Siguret, M Alhenc-Gelas, et al.
Annales De Biologie Clinique|August 10, 2000
[Myelodysplastic syndromes]C Garandeau, E Pautas, M Andreux, et al.
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]V Siguret, C Esquirol, M Debray, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Pathologie-Biologie|July 6, 2007
[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy]V Siguret
Annales De Biologie Clinique|March 1, 1997
[Biological diagnosis of hemoglobinopathies by phenotype analysis]V Siguret, J P Andreux
Annales De Biologie Clinique|October 1, 1998
[Evaluation of hemostasis in venous thromboembolism pathology]P Gaussem, V Siguret, M Aiach
La Revue De Medecine Interne|April 6, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion]C Moreau, V Siguret, M-A Loriot
Journal of Thrombosis and Haemostasis : JTH|August 9, 2011
No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudyV Siguret, I Gouin-Thibault, E Pautas, et al.
La Revue De Medecine Interne|March 26, 2003
[Oral anticoagulants in the elderly]M Debray, E Pautas, P Couturier, et al.
Pathologie-Biologie|May 1, 1989
[Frequency and severity of systemic infections caused by Streptococcus mitis and sanguis II in neutropenic children]T Leblanc, G Leverger, G Arlet, et al.
Journal of the American Geriatrics Society|December 16, 1998
Venous thrombosis in older people: prevalence of the factor V gene mutation Q506E André, V Siguret, M Alhenc-Gelas, et al.
Annales De Biologie Clinique|August 10, 2000
[Myelodysplastic syndromes]C Garandeau, E Pautas, M Andreux, et al.
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]V Siguret, C Esquirol, M Debray, et al.
Pageof 5